How Well Do Results From Randomized Clinical Trials and/or Recommendations for Implantable Cardioverter-Defibrillator Programming Diffuse Into Clinical Practice?


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
05 02 2019
Historique:
entrez: 5 2 2019
pubmed: 5 2 2019
medline: 25 2 2020
Statut: ppublish

Résumé

Background Inappropriate implantable cardioverter-defibrillator programming can be detrimental. Whether trials/recommendations informing best implantable cardioverter-defibrillator programming (high-rate cutoff and/or extended duration of detection) influence practice is unknown. Methods and Results We measured reaction to publication of MADIT-RIT (Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy; 2012) and the Consensus Statement (2015) providing generic programming parameters, in a national cohort of implantable cardioverter-defibrillator recipients, using the ALTITUDE database (Boston Scientific). Yearly changes in programmed parameters to either trial-specified or class 1 recommended parameters (≥185 beats per minute or delay ≥6 seconds) were assessed in parallel. From 2008 to 2017, 232 982 patients (aged 67±13 years; 28% women) were analyzed. Prevalence of MADIT- RIT -specific settings before publication was <1%, increasing to 13.6% in the year following. Thereafter, this increased by <6% over 5 years. Among preexisting implants (91 171), most patients (58 739 [64.4%]) underwent at least 1 in-person device reprogramming after trial publication, but <2% were reprogrammed to MADIT - RIT settings. Notably, prevalence of programming to ≥185 beats per minute or delay ≥6 seconds was increased by MADIT - RIT (57.4% in 2013 versus 40.2% at baseline), but the following publication of recommendations had minor incremental effect (73.2% in 2016 versus 70.8% in 2015). High-rate cutoff programming was favored almost 2-fold compared with extended duration throughout the test period. Practice changes demonstrated large interhospital and interstate variations. Conclusions Trial publication had an immediate effect during 1 year postpublication, but absolute penetration was low, and amplified little with time. Consensus recommendations had a negligible effect. However, generic programming was exercised more widely, and increased after trial publication, but not following recommendations.

Identifiants

pubmed: 30712432
doi: 10.1161/JAHA.117.007392
pmc: PMC6405582
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e007392

Références

N Engl J Med. 2012 Dec 13;367(24):2275-83
pubmed: 23131066
JAMA. 2015 Jul 28;314(4):337-8
pubmed: 26219044
Heart Rhythm. 2009 Dec;6(12):1727-34
pubmed: 19959119
Eur Heart J. 2013 Feb;34(8):605-14
pubmed: 23242192
Europace. 2013 Jun;15 Suppl 1:i11-i13
pubmed: 23737222
Circulation. 2013 Nov 26;128(22):2447-60
pubmed: 24166574
Stroke. 2012 Dec;43(12):3442-53
pubmed: 22858728
Circulation. 2010 Jul 27;122(4):325-32
pubmed: 20625110
Heart Rhythm. 2015 Jul;12(7):e69-100
pubmed: 25981148
Europace. 2013 Jun;15 Suppl 1:i69-i71
pubmed: 23737236
Circulation. 2013 Nov 26;128(22):2372-83
pubmed: 24043302
Circ Cardiovasc Qual Outcomes. 2017 Feb;10(2):
pubmed: 28196927
Circulation. 2010 Dec 7;122(23):2359-67
pubmed: 21098452
Circ Heart Fail. 2008 Jul;1(2):98-106
pubmed: 19808279
J Am Coll Cardiol. 2015 Jun 23;65(24):2601-2610
pubmed: 25983008
Circ Heart Fail. 2015 May;8(3):473-80
pubmed: 25747700
JACC Clin Electrophysiol. 2017 Nov;3(11):1275-1282
pubmed: 29759624
Heart Rhythm. 2015 Mar;12(3):545-553
pubmed: 25460168
Heart Rhythm. 2016 Feb;13(2):e50-86
pubmed: 26607062
Eur Heart J. 2014 May 21;35(20):1345-52
pubmed: 24595864
JAMA. 2013 May 8;309(18):1903-11
pubmed: 23652522
J Am Coll Cardiol. 2013 Nov 19;62(21):1931-1947
pubmed: 24036027
Circulation. 2016 Jan 19;133(3):273-81
pubmed: 26635400
J Am Heart Assoc. 2019 Feb 5;8(3):e007392
pubmed: 30712432
Circ Arrhythm Electrophysiol. 2017 Sep;10(9):
pubmed: 28916511
Circulation. 2014 Jul 22;130(4):308-14
pubmed: 24838360
J Am Coll Cardiol. 2012 Oct 16;60(16):1484-8
pubmed: 22999725
J Am Coll Cardiol. 2018 Jul 24;72(4):351-366
pubmed: 30025570
Circ Cardiovasc Qual Outcomes. 2017 Jan;10(1):e000022
pubmed: 27993943

Auteurs

Niraj Varma (N)

1 Cleveland Clinic Cleveland OH.

Paul Jones (P)

2 Boston Scientific St. Paul MN.

Nicholas Wold (N)

2 Boston Scientific St. Paul MN.

Edmond Cronin (E)

3 Hartford Hospital Hartford CT.

Kenneth Stein (K)

2 Boston Scientific St. Paul MN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH